CSF1R and COVID-19: In contrast, for the SD patient at the recovery stage (SDR) (COV029→COV126), the percentage of (CD68-CSF1R-IL1BhiCD14+)classical monocytes at the second time point resumed to the level similar to the healthy control (HC) group (Figure 5C), suggesting that (CD68-CSF1R-IL1BhiCD14+)classical monocytes may play an important role in the pathogenesis of COVID-19.